“o.itemList.length” “this.config.text.ariaShown”
“This.config.text.ariaFermé”
ANN ARBOR, MI / ACCESSWIRE / September 2, 2020 / ENDRA Life Sciences Inc.(“ENDRA”) (NASDAQ: NDRA), the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced that it will provide control at the LD 500 Virtual Day, organized through LD Micro and taking place almost September 1-42020.La the company’s provision will be held on Thursday, September 3, 2020 at 24:00 a.m.Et.
Francois Michelon, president and CEO of ENDRA, is expected to conduct a virtual presentation during the convention as follows and participate in individual meetings during the day.
LD 500 Virtual Investor Conference
Date:
Thursday, September 3, 2020
Time:
2:00 p.m. East Time – Track 4
Webcast:
https://www.webcaster4.com/Webcast/Page/2019/36782
A live audio webcast and convention presentation files will be available in the webcast link above.For more information about the LD 500 Virtual Investor Conference or to schedule an individual convention, please contact your LD Micro representative.
On ENDRA Life Sciences’ proposal, Inc.se concerned.TAEUS is designed to paint in conjunction with one million recent ecographers in international use.TAEUS first focuses on measuring fats in the liver as a means of comparing and tracking NAFLD and NASH, a chronic liver disease that affects more than one billion people internationally and for which there is no practical diagnostic tool.Beyond the liver, ENDRA is exploring several other TAEUS clinical programs, adding visualization of surgical procedures based on tissue temperature energy.
Forward-Looking Statements All statements in this press release that are not based on ancient facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1933. 1934. Forward- Forward-looking statements, which are based on safe assumptions and describe our long-term plans, methods, and expectations, can sometimes be learned through the use of forward-looking terms such as “believe”, “expect”, “may”, “will”, “should”, “may simply”, “seek”, “intend”, “plan”, “objective”, “estimate”, “anticipate” or other comparable terms. Examples of forward-looking statements include, but are not limited to, estimates of the timing of long-term occasions and achievements, such as expectations related to the commercialization of the TAEUS device, the status quo of benchmarking sites, and initial sales in Europe. Arrangement to obtain regulatory approval from the US Food and Drug Administration and expectations regarding EN DRA’s Business Strategy. Forward-looking statements involve inherent dangers and uncertainties that may cause actual effects to differ materially from the forward-looking statements, due to various factors, including, but not limited to, our ability to expand commercially viable technology; receipt of mandatory regulatory approvals; have an effect of COVID-19 on our business plans; our ability to locate and maintain progression partners, the market acceptance of our technology, the quantity and nature of the festival in our industry; our ability to protect our intellectual property; and the other dangers and insecurities described in documents filed through ENDRA with the Securities and Exchange Commission. The forward-looking statements made in this press release refer only to the date of this press release, and ENDRA assumes no legal responsibility to update such forward-looking statements to reflect actual effects or adjustments to expectations, unless otherwise indicated. otherwise in the Law.
Company Contact:
David Wells Chief Financial Officer (734) [email protected]
Media Contact:
Denise DiMeglio (610) [email protected]
Investor Relations Contact:
Joe Hassett (484) [email protected]
SOURCE: ENDRA Life Sciences Inc.
See the edition in accesswire.com: https://www.accesswire.com/604539/ENDRA-Life-Sciences-to-Present-at-the-LD-Micro-500-Virtual-Conference